Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass

Shvetank Agarwal, Beth Ullom, Yasser Al-Baghdadi, Michael Okumura

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Use of argatroban as an alternative to heparin during cardiopulmonary bypass (CPB) in patients with heparin-induced thrombocytopenia has gained some attention in the past two decades. Dosing of argatroban during CPB is complex due to lack of complete understanding of its pharmacokinetic profile and the various elements during CPB that may alter its plasma levels. We report a case where the challenges in dosing argatroban led to failure to provide adequate anticoagulation during CPB, as evidenced by clot formation in the oxygenator, and extensive bleeding in the postoperative period.

Original languageEnglish (US)
Pages (from-to)106-110
Number of pages5
JournalJournal of Anaesthesiology Clinical Pharmacology
Issue number1
StatePublished - Jan 2012
Externally publishedYes


  • Anti-coagulation
  • argatroban
  • cardio-pulmonary bypass
  • heparin alternative
  • heparin induced thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass'. Together they form a unique fingerprint.

Cite this